Please provide your email address to receive an email when new articles are posted on . The phase 2 DR:EAM clinical trial did not meet the endpoint of the percentage of patients with a two-step or ...
These results suggest an important takeaway: how blood sugar is controlled matters. A nutrient-dense, plant-based diet that helps maintain healthy blood sugar levels may lower your risk of diabetic ...
In A Nutshell Metformin, a common diabetes medication costing less than $10 monthly, was linked to 37% fewer cases of ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...
According to the phase II/III DIAMOND trial, there was early evidence of efficacy for OCS-01 eye drops in patients with diabetic macular edema (DME) compared with sham. The findings were reported at ...
Links between gut dysfunction and the eye may reveal therapeutic strategies for individuals with diabetic retinopathy ...
OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...
Please provide your email address to receive an email when new articles are posted on . EXN407 met primary endpoints of safety and tolerability and also demonstrated decreases in vascular leakage and ...
CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...
TOKYO, Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results